Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
1998-08-24
2001-04-24
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S423000, C424S427000, C424S430000, C424S434000, C424S435000, C424S436000, C424S444000, C424S450000, C424S489000, C424S498000, C514S821000, C514S887000, C514S966000, C514S967000, C514S968000
Reexamination Certificate
active
06221401
ABSTRACT:
BACKGROUND OF THE INVENTION
Conventional drug delivery technology, which in the past has concentrated on improvements in mechanical devices such as implants or pumps to achieve more sustained release of drugs, is now advancing on a microscopic and even molecular level. Recombinant technology has produced a variety of new potential therapeutics in the form of peptides and proteins and these successes have spurred the search for newer and more appropriate delivery and targeting methods and vehicles.
Microencapsulation of drugs within biodegradable polymers and liposomes has achieved successes in improving the pharmacodynamics of a variety of drugs such as antibiotics and chemotherapeutic agents. For example, unilamellar vesicles are currently used as drug delivery vehicles for a number of compounds where slow, sustained release or targeted release to specific sites in the body are desired. The drug to be released is contained within the aqueous interior of the vesicle and release is achieved by slow permeation through the vesicle bilayer. A variety of modifications of the unilamellar vesicle membrane have been attempted, including polymerizing or crosslinking the molecules in the bilayer to enhance stability and reduce permeation rates, and incorporating polymers into the bilayer to reduce clearance by macrophages in the bloodstream.
One example of such a vesicle structure is known as Depofoam. Depofoam is a multivesicular particle that is created by multiple emulsification steps. A defined lipid composition is dissolved in a volatile solvent. The dispersed lipids in solvent are vigorously mixed with water to form a first emulsion, designated a solvent continuous emulsion.
This first emulsion is then added to a second water/solvent emulsion and emulsified to form a water in solvent in water double emulsion. The solvent is removed from the mixture resulting in discrete foam-like spherical structures consisting of bilayer separated water compartments. The minimum size of these structures is about 5-10 microns. Depofoam does not include a distinct bilayer structure that encapsulates the multivesicular particles, i.e., there are no individual, distinct interior vesicles. Therefore, the interior compartment must share bilayer walls.
Liposomes are sealed, usually spherical, either unilamellar or multilamellar vesicles which are capable of encapsulating a variety of drugs. Liposomes are the most widely studied vesicles to date and they can be formulated with a variety of lipid types and compositions that can alter their stability, pharmacokinetics and biodistribution. A major disadvantage of both multilamellar and unilamellar liposomes as delivery systems is their size, which prevents them from crossing most normal membrane barriers and limits their administration to the intravenous route. In addition, their tissue selectivity is limited to the reticuloendothelial cells, which recognize them as foreign microparticulates and then concentrates the liposomes in tissues such as the liver and spleen.
Polymers have also been used as drug delivery systems. They generally release drugs by (1) polymeric degradation or chemical cleavage of the drug from the polymer, (2) swelling of the polymer to release drugs trapped within the polymeric chains, (3) osmotic pressure effects, which create pores that release a drug which is dispersed within a polymeric network, and/or (4) simple diffusion of the drug from within the polymeric matrix to the surrounding medium.
With the success and drawbacks of these microencapsulation vehicles, today the challenge is to produce better and more efficient microencapsulation vehicles to enhance drug delivery. The present invention is directed to meeting that challenge.
SUMMARY OF THE INVENTION
The present invention provides a bilayer structure for encapsulating multiple containment units, e.g., polymer containment units. Containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.
The invention provides compositions comprising the bilayer structure of the invention and multiple containment units. Preferably, the containment units are aggregated.
In one embodiment of the invention, these compositions include vesosomes. Vesosomes have a bilayer structure that encapsulates multiple containment units in the form of vesicles. Generally, the multiple vesicles are aggregated. Vesicles can be unilamellar or multilamellar.
The vesicles can either be of similar size and composition or of varied size and composition. Preferably, each vesicle is attached to another (or aggregated) via ligand-receptor or antibody-antigen interactions.
Further, the encapsulating bilayer structure can attach to the aggregated vesicles via ligand-receptor interactions. By optimizing both the exterior bilayer structure and the interior vesicle compositions, the size and size distribution of the interior vesicles, the overall size of the vesosome, the nature of the attachments of the vesicles, and the type of additives to the outer bilayer (such as polymers or specific recognition sites), an extremely versatile drug delivery system can be developed for a variety of applications.
REFERENCES:
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 5004566 (1991-04-01), Schnur et al.
patent: 5492696 (1996-02-01), Price et al.
patent: 5576017 (1996-11-01), Kim
patent: 5618560 (1997-04-01), Bar-Shalom et al.
patent: 5643574 (1997-07-01), Gould-Fogerite et al.
patent: 5723147 (1998-03-01), Kim et al.
Chiruvolu, Shivkumar et al., “Higher Order Self-Assembly of Vesicles by Site Specific Binding,”Science,Jun. 17, 1994, 2364:1753-6. (Exhibit 6).
Papahadjopoulos, D. et al., “Effect of Proteins on Thermotropic Phase Transistors of Phospholipid Membranes,”Biochimica et Biophysica Acta,1975, 410:317-35. (Exhibit 7).
Papahadjopoulos, D. et al., “Cochleate Lipid Cylinders: Formation by Fusion of Unilamellar Lipid Vesciles,”Biochimica et Biophysica Acta,1975, 394:483-91. (Exhibit 8).
Papahadjopoulos, D. et al., “Induction of Fusion in Pure Phospholipid Membranes by Calcium Icons and Other Divalent Metals,”Biochimica et Biophysica Acta,1976, 448:265-83. (Exhibit 9).
Freireich, Emil J. et al., “Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey and Man,”Cancer Chemotherapy Reports,May 1996, 50(4):219-44. (Exhibit 10).
Kennedy Michael
Walker Scott
Zasadzinski Joseph
Mandel & Adriano
Spear James M.
The Regents of the University of California
LandOfFree
Bilayer structure which encapsulates multiple containment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bilayer structure which encapsulates multiple containment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bilayer structure which encapsulates multiple containment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2522001